A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
← catalyst calendarNCT06253130 · readout in 286 d
Sponsored by Eikon Therapeutics (industry) · EIKN — their whole pipeline →. With Impact Therapeutics, Inc..
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
156estimated
Sites
57
Countries
Australia, Canada, China +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-11 | actual | When the study began enrolling |
| Primary completion | 2027-06-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-01 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumor
Intervention
- Drug: IMP1734
Primary outcomes
what the primary-completion date above is the date OFNumber of subjects with adverse events, treatment emergent adverse events or serious adverse events
measured Consent to 30 + 7 days post last dose of IMP1734
Maxim Tolerated Dose or Recommended Dose for Expansion
measured DLT period is from the first dose of the study drug until the last day of the first cycle
Permalink · EIKN's whole pipeline · Catalyst calendar · Every registered study · What changed